3,4-Methylenedioxy-N-ethylamphetamine

MDEA
Clinical data
Other namesMDEA; MDE; 3,4-Methylenedioxy-N-ethylamphetamine; N-Ethyl-MDA; Eve; EA-1304; EA1304; PAL-192; PAL192; ASR-1003; ASR1003
Routes of
administration		Oral, insufflation, injection, rectal
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic including CYP2D6 and CYP3A4
Onset of action20–85 minutes
Elimination half-life(R)-MDEA: 7.5 ± 2.4 hours
(S)-MDEA: 4.2 ± 1.4 hours
ExcretionRenal
Identifiers
  • 1-(1,3-Benzodioxol-5-yl)-N-ethylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.231.031
Chemical and physical data
FormulaC12H17NO2
Molar mass207.273 g·mol−1
3D model (JSmol)
  • CCNC(C)Cc1ccc2OCOc2c1

3,4-Methylenedioxy-N-ethylamphetamine (MDEA; also called MDE and colloquially, Eve) is an empathogenic psychoactive drug. MDEA is a substituted amphetamine and a substituted methylenedioxyphenethylamine. MDEA acts as a serotonin, norepinephrine, and dopamine releasing agent and reuptake inhibitor.

Possession of MDEA is illegal in most countries. Some limited exceptions exist for scientific and medical research.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.